BioSig appoints Parcl co-founders as strategic advisors

LOS ANGELES & VANCOUVER -

BioSig Technologies, Inc. (NASDAQ:BSGM), a medical technology company, announced today the appointment of Trevor Bacon and Kellan Grenier, co-founders of Parcl, as Strategic Advisors to its subsidiary, Streamex Exchange Corporation. The appointments aim to leverage their expertise in decentralized finance and real-world asset tokenization to advance BioSig’s commodity market initiatives.

Bacon and Grenier’s background is rooted in financial markets and blockchain technology. Bacon, CEO of Parcl, has over a decade of experience in finance, including roles at Barclays and as a portfolio manager at hedge funds. Grenier, COO of Parcl, has served as an equity analyst and has been involved in blockchain for over five years. Their platform, Parcl, allows users to trade on real estate markets without owning physical properties.

Henry McPhie, CEO of BioSig and Co-Founder of Streamex, praised the new advisors, saying their experience in creating advanced decentralized trading platforms makes them well-suited to support BioSig and Streamex’s mission to tokenize and trade real-world assets.

Bacon expressed enthusiasm for advising BioSig and Streamex, noting the transformative potential of tokenizing real-world assets. Grenier echoed this sentiment, highlighting the alignment with their belief in programmable financial assets and blockchain-based access to new asset classes.

The addition of Bacon and Grenier expands the advisory board at BioSig and Streamex, which includes notable figures such as Frank Giustra, Sean Roosen, and Mathew August, each bringing expertise in commodities, mining, and capital markets, respectively.

BioSig’s PURE EP™ Platform is an FDA 510(k) cleared system designed to enhance the clarity of intracardiac signals for electrophysiologists. Streamex, as a wholly owned subsidiary of BioSig, focuses on tokenizing real-world assets in the commodities sector, aiming to revolutionize commodity finance with blockchain technology.

The company’s forward-looking statements caution that actual results may differ from those anticipated, and are subject to risks and uncertainties. This announcement is based on a press release statement and does not imply endorsement of claims. InvestingPro data reveals the stock has delivered remarkable returns, gaining 293% over the past year, though technical indicators suggest the stock may be overbought. Subscribers can access 15 additional ProTips and comprehensive financial metrics to make more informed investment decisions.

In other recent news, BioSig Technologies has reported several significant developments. The company recently completed a merger with Streamex Exchange Corp, a tokenization company focused on commodities, making Streamex a wholly owned subsidiary. This strategic move has led Ascendiant Capital to raise its price target for BioSig from $2.50 to $10.00, maintaining a Buy rating. Despite this, Ascendiant Capital has adjusted its earnings per share estimates for BioSig to $(0.25) for fiscal year 2025, keeping revenue estimates at approximately $0, pending further financial details post-merger.

BioSig has also made key appointments following the merger. Mitch Williams has been appointed as Chief Investment Officer, bringing over 20 years of experience in capital markets to advance the company’s initiatives in tokenizing real-world assets. Additionally, Sean Roosen has joined as a Strategic Advisor to Streamex, expected to contribute significantly to the company’s mission in the commodities market.

Furthermore, BioSig has regained compliance with Nasdaq’s minimum bid price requirement after its common stock maintained a closing bid price of at least $1.00 per share for 10 consecutive business days. This compliance is a positive development, ensuring BioSig remains listed on the NASDAQ Capital Market. These recent developments reflect BioSig’s strategic efforts to enhance its position in the market and leverage new opportunities in the digital economy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.